Aleos Capital, through its fund Aleos Fund I, has acquired a majority stake in Eggnovo, the European leader in high-value functional ingredients derived from eggshell membrane, used in nutraceutical, cosmetic, veterinary, and food applications. An international investor with sector experience will also invest in the company alongside Aleos Capital.
Founded in 2012 and headquartered in Villatuerta (Navarra), Eggnovo develops clinically validated, proprietary functional ingredients using its own extraction technology, which includes several patents. As part of a circular economy model embedded in the company’s DNA, Eggnovo processes several million eggshells daily from a broad network of egg producers, transforming what would otherwise be a byproduct of the food industry into high-value-added ingredients.
Eggshell membrane is a natural ingredient composed of a matrix of over 400 bioactive compounds, including collagen, elastin, and hyaluronic acid. Its unique composition positions it as a next-generation, more bioavailable alternative to traditional collagen and forms the basis of nutraceutical and health products aimed at improving joint mobility, skin health, and overall wellbeing. In line with its approach to full utilization of the eggshell, the company also uses the shell’s calcium carbonate to develop ingredients for bone health.
Eggnovo markets its products in over 45 countries, generating around 90% of its revenue from international markets, with a diversified B2B customer base that includes some of the world’s leading nutraceutical and health brands.
The company has experienced strong growth in recent years, with revenues increasing by more than 30% annually between 2020 and 2025, surpassing €10 million. Eggnovo employs approximately 50 people and has established itself as the European leader in functional eggshell membrane ingredients, supported by more than 20 clinical studies and proprietary technology. It continues to expand its innovation pipeline with next-generation soluble forms designed to broaden applications and enhance bioavailability.
Eggnovo’s CEO and principal shareholder, Juan Pablo Gallego, will reinvest significantly in the company and continue to lead the business alongside the current management team, working closely with Aleos in the company’s next development phase. The current main shareholders of Eggnovo will also reinvest in the company.
The alliance with Aleos aims to support Eggnovo’s growth and maintain its strong expansion trajectory in recent years, consolidating its presence in key international markets, particularly in Asia and the United States. The plan includes several growth avenues, such as strengthening its position in nutraceuticals and developing new natural applications in areas like cosmetics, food and beverages, and eco-industrial solutions, supported by increased investment in R&D and technology
cloud technology axon
Across the portfolio, these efforts contributed to measurable progress...
